Tags

Type your tag names separated by a space and hit enter

Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome.
Methods Find Exp Clin Pharmacol. 2009 Dec; 31(10):655-9.MF

Abstract

Symptoms of irritable bowel syndrome (IBS) have a profound impact on quality of life for many patients and current treatments are sometimes unsatisfactory. This controlled pilot study was conducted to evaluate effects of the proprietary GanedenBC(30) (Bacillus coagulans GBI-30, 6086) probiotic on IBS symptoms, in a randomized, double-blind, placebo-controlled clinical trial including patients with diarrhea-predominant IBS (IBS-D). Patients were randomized to receive either B. coagulans GBI-30, 6086 or placebo once a day for 8 weeks. Patients filled out a quality-of-life questionnaire, and self-assessment diaries were provided to record stool count and consistency, symptom severity, and medication consumption. Of the 61 patients enrolled, six did not meet the inclusion criteria and three were lost to follow-up. Of the remaining 52 patients with IBS-D, the average number of bowel movements per day was significantly reduced for patients treated with B. coagulans GBI-30, 6086 when compared to placebo (P = 0.042). Large variability in baseline scores prevented the assessment of severity scores and quality of life. This small pilot study provides evidence that the proprietary B. coagulans GBI-30, 6086 probiotic is safe and effective for reducing daily bowel movements in patients with IBS-D.

Authors+Show Affiliations

Accelovance Inc., Peoria, Illinois 61602, USA. bjdolin@yahoo.com

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

20140275

Citation

Dolin, B J.. "Effects of a Proprietary Bacillus Coagulans Preparation On Symptoms of Diarrhea-predominant Irritable Bowel Syndrome." Methods and Findings in Experimental and Clinical Pharmacology, vol. 31, no. 10, 2009, pp. 655-9.
Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;31(10):655-9.
Dolin, B. J. (2009). Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods and Findings in Experimental and Clinical Pharmacology, 31(10), 655-9. https://doi.org/10.1358/mf.2009.31.10.1441078
Dolin BJ. Effects of a Proprietary Bacillus Coagulans Preparation On Symptoms of Diarrhea-predominant Irritable Bowel Syndrome. Methods Find Exp Clin Pharmacol. 2009;31(10):655-9. PubMed PMID: 20140275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. A1 - Dolin,B J, PY - 2010/2/9/entrez PY - 2010/2/9/pubmed PY - 2010/4/21/medline SP - 655 EP - 9 JF - Methods and findings in experimental and clinical pharmacology JO - Methods Find Exp Clin Pharmacol VL - 31 IS - 10 N2 - Symptoms of irritable bowel syndrome (IBS) have a profound impact on quality of life for many patients and current treatments are sometimes unsatisfactory. This controlled pilot study was conducted to evaluate effects of the proprietary GanedenBC(30) (Bacillus coagulans GBI-30, 6086) probiotic on IBS symptoms, in a randomized, double-blind, placebo-controlled clinical trial including patients with diarrhea-predominant IBS (IBS-D). Patients were randomized to receive either B. coagulans GBI-30, 6086 or placebo once a day for 8 weeks. Patients filled out a quality-of-life questionnaire, and self-assessment diaries were provided to record stool count and consistency, symptom severity, and medication consumption. Of the 61 patients enrolled, six did not meet the inclusion criteria and three were lost to follow-up. Of the remaining 52 patients with IBS-D, the average number of bowel movements per day was significantly reduced for patients treated with B. coagulans GBI-30, 6086 when compared to placebo (P = 0.042). Large variability in baseline scores prevented the assessment of severity scores and quality of life. This small pilot study provides evidence that the proprietary B. coagulans GBI-30, 6086 probiotic is safe and effective for reducing daily bowel movements in patients with IBS-D. SN - 0379-0355 UR - https://www.unboundmedicine.com/medline/citation/20140275/Effects_of_a_proprietary_Bacillus_coagulans_preparation_on_symptoms_of_diarrhea_predominant_irritable_bowel_syndrome_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=6&p_RefId=1441078 DB - PRIME DP - Unbound Medicine ER -